Thank you for donating!

You can donate using the following services.


  1. 06.03.20

    Open Letter to Rare Disease Community from Joe Fitzpatrick, Minister for Public Health, Sport and Wellbeing

    An open letter to the rare disease community updating on Scotland's position with regard to rare disease. The letter sets out detailed progress with regards to its the three priorities of the Rare Disease Strategic Oversight Group (RDSOG); coordination of care,raising awareness of rare disease amongst health professionals and research.

    Read more
  2. 05.03.20

    INHERITED METABOLIC DISEASE AND CORONAVIRUS (COVID-19) Advice for patients / parents / guardians

    Advice for patients / parents / guardians regarding Coronavirus (COVID-19)...

    Read more
  3. 04.03.20

    IntraBio Extension Phase for Niemann-Pick C Accepted in United States

    Oxford, UK / IntraBio Inc. is pleased to announce that the Extension Phase for the IB1001-201 Clinical Trial has been accepted by the FDA (US Food and Drug Administration). The Extension Phase has also been previously approved by all European countries in which the trial is being conducted, including Germany, Slovakia, Spain, and the UK.

    Read more
  4. 02.03.20

    Cyclo Therapeutics Announces Positive Feedback from FDA on its Pivotal Trial Design for Trappsol® Cyclo™ for Niemann-Pick Disease Type C1

    Company next plans to meet with European Medicines Agency in second quarter 2020...

    Read more
  5. 20.02.20

    Cyclo Therapeutics Announces Completion of Enrollment in its Phase I/II Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

    Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease, today announced that it has completed patient enrollment in its Phase I/II trial to evaluate the safety, tolerability, and efficacy of Trappsol® Cyclo™ administered intravenously to Niemann-Pick Disease Type C1 (NPC1) patients...

    Read more